PERSONETICS
Personetics, the global leader in financial data-driven customer engagement for financial services today released a report titled Spotlight On Europe: Banks Need To Nurture Customers’ Financial Well-Being. The report, based on a study conducted by Forrester Consulting on behalf of Personetics, details the opportunities and challenges associated with leveraging money management tools to enhance customer engagement and increase lifetime value.
“Now more than ever, customers demand greater control of their finances and expect their banks to deliver real-time, financial data-driven personalised advice and long-term planning,” said Dorel Blitz, VP of Strategy & Business Development at Personetics. “Yet Forrester’s report reveals that existing Personal Financial Management (PFM) tools are neither meeting customer expectations nor delivering business impact for banks. The banks that will thrive are those which will take advantage of the opportunity to provide advanced and proven money management capabilities.”
Forrester based its conclusions on responses from key banking decision-makers. The report shows that while most banks offer basic PFM and money management capabilities there is a growing, urgent need for both banks and their customers to “evolve their approach in order to successfully raise customers’ levels of financial well-being.”
For example, the European survey revealed disappointingly low levels of customer adoption and engagement with digital money management tools. Although nearly three-quarters (73%) of bankers say they already offers customers some sort of digital money management tool, 77% state that fewer than half of their customers actively use these tools.
The report found that adoption is low because existing money management tools fail to deliver tangible outcomes for customers. Today’s money management tools follow a one-size-fits-all approach, meaning they put too much onus on the end user and fail to help customers achieve their financial goals.
Mr. Blitz added: “The good news is that banks are alive to the issues they face. Now it’s a matter of finding the right path forward, through proactive, hyper-personalised solutions at scale that can make a difference today.”
Below are the core findings across Europe.
Banks have high expectations for money management solutions.
When asked about the benefits of implementing digital technologies for this purpose, the top three benefits were increased customer engagement (47%), increased revenue through upsell and cross-sell (43%) and new customer acquisition (43%).
Traditional PFM fails to deliver effective customer outcomes.
One of the main challenges in deploying these digital capabilities is the absence of an enterprise-wide approach to enhancing customer outcomes. Just over half of banks say they can provide sufficient personalised financial insights and advice based on customers’ financial data. This leaves a significant number of banks without the means to deliver competitive and appealing offers and products for their customers.
A major opportunity exists for innovative banks.
Banks should use an advanced money management platform to deliver business impact, increase revenue, profitability, and customer lifetime value. To do this, financial institutions need to partner with the right vendor and invest in advanced capabilities, adopt a financial data-driven approach, and deliver solutions that customers need when they need them.
Read the full report here.
About Personetics
Personetics is a global financial data-driven personalised customer engagement platform for financial services. The company’s mission is to shape the future of “Self-Driving Finance,” where financial institutions can proactively help consumers improve their financial well-being and achieve financial goals.
Personetics serves more than 100 financial institutions in 32 global markets and reaches 140 million customers. The company is backed by leading venture capital and private equity investors, with offices in New York, London, Tel Aviv, Singapore, Tokyo, Paris, Spain, and Australia.
Learn more at personetics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005691/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
